戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 so observed in patient samples obtained from transurethral resection.
2 ncer with particularly high recurrence after transurethral resection.
3 a safe, effective and durable alternative to transurethral resection.
4                           Patients underwent transurethral resection and induction CRT to 40 Gy.
5                                              Transurethral resection and instillation of perioperativ
6  carcinomas of the bladder were treated with transurethral resection and intravesical bacillus Calmet
7 rficial bladder cancer is still managed with transurethral resection and perioperative instillation o
8 patients who underwent either enucleation or transurethral resection as their initial treatment.
9                                              Transurethral resection biopsies of the prostatic urethr
10 e bladder cancer, combined-modality therapy (transurethral resection bladder tumor [TURBT], radiation
11  of those rendered T(1) at second look after transurethral resection bladder tumor, most still requir
12 than five cases in urologists, with previous transurethral resection experience.
13 y deferred based on the clinical response to transurethral resection followed by systemic therapy.
14                Two to 4 weeks after complete transurethral resection, gemcitabine was administered in
15                                      Bipolar transurethral resection is a novel approach in treatment
16 nstillation of chemotherapeutic agents after transurethral resection is quickly becoming the standard
17                                              Transurethral resection is the cornerstone treatment for
18              Despite current treatment after transurethral resection of a bladder tumor, recurrences
19 etect urothelial bladder cancer (UBC) before transurethral resection of bladder cancer (TURBT), and (
20 y (BLC) with hexaminolevulinate (HAL) during transurethral resection of bladder cancer improves detec
21 recurrence (defined as receipt of subsequent transurethral resection of bladder tumor >3 months after
22                                              Transurethral resection of bladder tumor (TURBT) is the
23 s the use of intravesical chemotherapy after transurethral resection of bladder tumor before and afte
24  (BCG) induction and maintenance (I+M) after transurethral resection of bladder tumor is standard of
25 s after index diagnosis of NMIBC and initial transurethral resection of bladder tumor), progression (
26 sparing trimodal therapy (TMT) that combines transurethral resection of bladder tumor, chemotherapy f
27                    After undergoing complete transurethral resection of bladder tumor, patients recei
28                       Concurrently performed transurethral resection of bladder tumor-TURP seems onco
29 he number of patients requiring a procedure (transurethral resection of bladder tumors [TURBT] or off
30 ) often have recurrence or progression after transurethral resection of bladder tumour (TURBT) and su
31                                              Transurethral resection of bladder tumour (TURBT) is a d
32                                 An effective transurethral resection of bladder tumour (TURBT) is ess
33                                              Transurethral resection of bladder tumour (TURBT) was pe
34   Randomisation was stratified by results of transurethral resection of bladder tumour (visibly compl
35                             All patients had transurethral resection of bladder tumour and twice-dail
36 ores to compare trimodality therapy (maximal transurethral resection of bladder tumour followed by co
37 h-risk non-muscle-invasive bladder cancer is transurethral resection of bladder tumour followed by in
38                                              Transurethral resection of bladder tumour within 12 week
39 apy or trimodality therapy (that is, maximal transurethral resection of bladder tumour, chemotherapy
40           Age (P =.78), race (P =.29), prior transurethral resection of prostate (P =.81), and treatm
41 as admitted with massive hematuria following transurethral resection of prostate for benign prostatic
42  of the procedures examined (P < .01, except transurethral resection of prostate, P = .76).
43 radiation delivered per treatment, and prior transurethral resection of prostate.
44                       All patients underwent transurethral resection of the bladder (TURB) and had hi
45 biomarker test, can predict the need for 2nd transurethral resection of the bladder (TURB) better tha
46  evidence of clinical CR and received a redo transurethral resection of the bladder tumor (reTURBT).
47                 Patients who received no LT, transurethral resection of the bladder tumor alone, or <
48                                            A transurethral resection of the bladder tumor and biopsy
49    Diagnostic cystoscopy in combination with transurethral resection of the bladder tumour are the st
50 preserving treatment (TMT) comprises maximal transurethral resection of the bladder tumour followed b
51 ons and partial obstructions respond best to transurethral resection of the ejaculatory ducts (TURED)
52 urgical retreatment (3.4%-21%) compared with transurethral resection of the prostate (5%) and holmium
53 01), prostatectomy (chi23 = 24.4; P = .001), transurethral resection of the prostate (chi23 = 51.3; P
54 rlson comorbidity score (P < .01), and prior transurethral resection of the prostate (OR, 1.65; P < .
55 state glands (> or = 60 cm3) or history of a transurethral resection of the prostate (TURP) as implan
56                                              Transurethral resection of the prostate (TURP) has long
57  with age, suggests that the frequent use of transurethral resection of the prostate (TURP) in recent
58 alised prostate cancer diagnosed by use of a transurethral resection of the prostate (TURP) in the UK
59                                              Transurethral resection of the prostate (TURP) is the st
60        Eight percent of patients underwent a transurethral resection of the prostate (TURP) within 2
61 eks after radical prostatectomy (trial 1) or transurethral resection of the prostate (TURP; trial 2)
62 ent choice over the past 10 years, replacing transurethral resection of the prostate as the standard
63 on and catheter removal policy can result in transurethral resection of the prostate being performed
64                     Optimizing each stage of transurethral resection of the prostate can result in re
65 rospective study of healthy men undergoing a transurethral resection of the prostate for benign prost
66                 The new technique of bipolar transurethral resection of the prostate has been studied
67 ht to the market over the past decade or so, transurethral resection of the prostate has been undergo
68                            At the same time, transurethral resection of the prostate has evolved into
69 i-centre studies in effectiveness of bipolar transurethral resection of the prostate is apparent.
70  the prostate are not as effective as either transurethral resection of the prostate or transurethral
71 sion of interest in surgical alternatives to transurethral resection of the prostate over the past de
72          In total, 156 prostate tissues from transurethral resection of the prostate procedures for b
73                                              Transurethral resection of the prostate remains a widely
74                                              Transurethral resection of the prostate remains the gold
75                                              Transurethral resection of the prostate remains the trea
76    Like many of the surgical alternatives to transurethral resection of the prostate this procedure s
77 sks the question of whether it will relegate transurethral resection of the prostate to an operation
78 -term results suggest equivalent efficacy to transurethral resection of the prostate with improved sa
79  diagnostic tumour samples (needle biopsy or transurethral resection of the prostate).
80  biopsy, laparoscopic radical prostatectomy, transurethral resection of the prostate, and ureteroscop
81                                 Surgery (eg, transurethral resection of the prostate, holmium laser e
82 agement was once limited to medical therapy, transurethral resection of the prostate, or open, relati
83 benign prostatic hyperplasia continues to be transurethral resection of the prostate, which is tradit
84 tatic outcomes compared to classic monopolar transurethral resection of the prostate.
85 dies have compared these two techniques with transurethral resection of the prostate.
86 tic hyperplasia was the electrocautery-based transurethral resection of the prostate.
87 tioned between pharmacological treatment and transurethral resection of the prostate.
88 e deemed high surgical risks for traditional transurethral resection of the prostate.
89 ajor advances that have occurred recently in transurethral resection of the prostate.
90 t challenge to the 'gold standard' status of transurethral resection of the prostate.
91 ggest there is no significant advantage over transurethral resection of the prostate.
92 etween June 2000 and July 2001 pertaining to transurethral resection of the prostate.
93 ate-specific antigen at diagnosis, and prior transurethral resection of the prostate.
94 nt of superficial bladder cancer is based on transurethral resection of the tumor with perioperative
95 nonmuscle invasive bladder cancer (NMIBC) is transurethral resection of the tumors, followed by intra
96                                         Both transurethral resection of the ureteral orifice (pluck)
97 f targeting of necrotic tissue from previous transurethral resections or chemotherapy are considered
98 including tumour understaging, the number of transurethral resection procedures received by the patie
99               RECENT FINDINGS: For improving transurethral resection quality, new optical enhancement
100 nd based on radical prostatectomy samples or transurethral resections rather than biopsy samples.
101                                              Transurethral resection remains the surgical mainstay fo
102 ime, a cystoscopy of his primary tumor and a transurethral resection revealed residual muscle-invasiv
103                               A total of 328 transurethral resection specimens from 232 patients were
104 itoring of irrigant absorption can eliminate transurethral resection syndrome.
105 ent have been explored, ranging from radical transurethral resection to concurrent chemoradiation.
106                              Electrosurgical transurethral resection (TUR) of the prostate (TURP) has
107 is); randomization within 12 months of first transurethral resection was required.
108             Only randomized comparisons with transurethral resection will tell us if it is a worthy c
109 -sparing trimodality treatment consisting of transurethral resection with chemoradiation.
110 ients with high-risk NMIBC involves complete transurethral resection with intravesical BCG therapy.
111 ontinues to be managed predominantly through transurethral resection with perioperative instillation
112 mainstay of diagnosis remains cystoscopy and transurethral resection, with enhanced optical technique

 
Page Top